Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1651 to 1665 of 8905 results

  1. Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal) (TA923)

    NICE is unable to make a recommendation on tabelecleucel (Ebvallo) for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus. This is because Pierre Fabre Ltd did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA923

  2. Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)

    Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

  3. Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

    Evidence-based recommendations on burosumab (Crysvita) for X-linked hypophosphataemia in children and young people.

  4. Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]

    In development Reference number: GID-TA10497 Expected publication date: TBC

  5. Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]

    In development Reference number: GID-TA10542 Expected publication date: TBC

  6. Gosuranemab for treating progressive supranuclear palsy [ID1607]

    Awaiting development Reference number: GID-TA10553 Expected publication date: TBC

  7. MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]

    In development Reference number: GID-TA10573 Expected publication date: TBC

  8. Rivaroxaban for treating chronic heart failure [ID1462]

    Awaiting development Reference number: GID-TA10393 Expected publication date: TBC

  9. Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

    Awaiting development Reference number: GID-TA10431 Expected publication date: TBC

  10. Dulaglutide for treating type 2 diabetes [ID1451]

    Awaiting development Reference number: GID-TA10439 Expected publication date: TBC

  11. Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

    In development Reference number: GID-TA10446 Expected publication date: TBC

  12. Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

    Awaiting development Reference number: GID-TA10453 Expected publication date: TBC

  13. Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]

    Awaiting development Reference number: GID-TA11300 Expected publication date: TBC

  14. Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]

    Awaiting development Reference number: GID-TA11404 Expected publication date: TBC

  15. Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]

    In development Reference number: GID-TA11410 Expected publication date: TBC